Clinical and Translational Results from PORTER, a Multi-cohort Phase 1 Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer. Read more about Clinical and Translational Results from PORTER, a Multi-cohort Phase 1 Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer.
Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy. Read more about Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy.
Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer. Read more about Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer.
Editor's Note: BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas. Read more about Editor's Note: BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors. Read more about Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors.
Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies. Read more about Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies.
Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment. Read more about Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment.
Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy. Read more about Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma. Read more about CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma.
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Read more about Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
